

REDACTION AND CONFIDENTIALITY LOG TO FORM HCMO-1 AND ATTACHMENTS

BATES REFERENCE	PARTY INFORMATION	INFORMATION REQUESTED	INFORMATION REDACTED	BASIS FOR REDACTION
HCMO-ATT-0001 to HCMO-ATT-0002	Party A, Party B, and Party C	<u>Appendix to HCMO-1 Form</u>	EIN Numbers of Entities	The parties request confidential treatment of certain information provided in the HCMO-1 Form. This information has not been made publicly available in any other forum. Further, this information is competitively sensitive and disclosure would enable competitors to identify and exploit vulnerabilities in the parties' operating model. and includes contact information for individuals. (<i>See</i> ORS 192.345(23)). Under ORS 415.501(13)(c), The Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a "material change transaction". As such, the parties are requesting further confidential treatment of these materials.
HCMO-ATT-0001 to HCMO-ATT-0002	Party B	<u>Appendix to HCMO-1 Form</u>	Transaction History	Party B requests confidential treatment of certain information provided in the HCMO-1 Form. This information has not been made publicly available in any other forum. Further, this information is competitively sensitive and disclosure would enable competitors to identify and exploit vulnerabilities in Party B's operating model and includes contact information for individuals.. (<i>See</i> ORS 192.345(23)). Under ORS 415.501(13)(c), The Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a "material change transaction". As such, Party B is requesting further confidential treatment of these materials.
HCMO-ATT-0001 to HCMO-ATT-0002	Party B	<u>Appendix to HCMO-1 Form</u>	Patients Served and Services Provided	Party B requests confidential treatment of certain information provided in the HCMO-1 Form. This information has not been made publicly available in any other forum. Further, this information is competitively sensitive and disclosure would enable competitors to identify and exploit vulnerabilities in Party B's operating model. (<i>See</i> ORS 192.345(23)). Under ORS 415.501(13)(c), The Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a "material change transaction". As such, Party B is requesting

BATES REFERENCE	PARTY INFORMATION	INFORMATION REQUESTED	INFORMATION REDACTED	BASIS FOR REDACTION
				further confidential treatment of these materials.
HCMO-FORM-024 to HCMO-FORM-028	Party A, Party B, and Party C	<u>HCMO-1b – Business Entities From</u>	EIN Numbers of Entities	The parties request confidential treatment of certain information provided in the HCMO-1b Form. This information has not been made publicly available in any other forum. Further, this information is competitively sensitive and disclosure would enable competitors to identify and exploit vulnerabilities in the parties’ operating model. and includes contact information for individuals. (<i>See</i> ORS 192.345(23)). Under ORS 415.501(13)(c), The Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a “material change transaction”. As such, the parties are requesting further confidential treatment of these materials.
HCMO-ATT-0003 to HCMO-ATT-0931	Party A, Party B, and Party C	<u>Appendix 9a</u>	Respective Pre-Merger Notification Filing and Attachments	The parties request confidential treatment of their respective Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended (“HSR Act”), filings and related materials submitted in connection with the Transaction. These materials contain highly sensitive, nonpublic business information, including strategic planning materials, competitive analyses, financial projections, transaction-related assessments, market evaluations, customer and supplier information, and other proprietary commercial information. Such information is treated as confidential internally, with access limited to legal, finance, corporate development, and senior management personnel, and is maintained in secure systems subject to confidentiality protocols. To the extent disclosed to third parties, including regulatory authorities and professional advisors, such information is provided pursuant to statutory protections, confidentiality obligations, or other applicable restrictions on

BATES REFERENCE	PARTY INFORMATION	INFORMATION REQUESTED	INFORMATION REDACTED	BASIS FOR REDACTION
				disclosure. Public disclosure could provide competitors, customers, suppliers, or other market participants with insight into the Parties' business strategies, financial performance, competitive positioning, acquisition criteria, and future plans, and could be used to cause competitive or economic harm. The materials were compiled specifically for regulatory review through significant investments of time, effort, and expense and are not readily ascertainable from public sources. (See ORS 192.345(2); ORS 415.501(13)(c); 15 U.S.C. § 18a(h)). Under ORS 415.501(13)(c), the Oregon Health Authority is prohibited from disclosing "all confidential information and documents that are not publicly available that are obtained in relation to a material change transaction". As such, the Parties request confidential treatment of these materials to the extent permitted by law.
HCMO-ATT-0932 to HCMO-ATT-1046	Party A and Party C	<u>Appendix 10e</u>	Financial Statements	The parties request confidential treatment of their Financial Statements. As nonpublic entities, this information has not been made publicly available in any other forum. Further, this information is competitively sensitive and disclosure would enable competitors to identify and exploit vulnerabilities in the companies' operating model (<i>See</i> ORS 192.345(2)). Under ORS 415.501(13)(c), the Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a "material change transaction." As such, the parties are requesting further confidential treatment of their Financial Statements, unless the parties provide written consent to publication.

BATES REFERENCE	PARTY INFORMATION	INFORMATION REQUESTED	INFORMATION REDACTED	BASIS FOR REDACTION
HCMO-ATT-1047 to HCMO-ATT-1119	Party B	<u>Appendix 11e</u>	Financial Statements	Party B requests confidential treatment of its Financial Statements. As a nonpublic entity, this information has not been made publicly available in any other forum. Further, this information is competitively sensitive and disclosure would enable competitors to identify and exploit vulnerabilities in the company's operating model (See ORS 192.345(2)). Under ORS 415.501(13)(c), the Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a “material change transaction.” As such, Party B is requesting further confidential treatment of its Financial Statements, unless Party B provides its written consent to publication.
HCMO-ATT-1169 to HCMO-ATT-1190	Party C	<u>Governance Documents</u>	Party C Bylaws	Party C requests confidential treatment of its nonpublic Governance Documents. As a nonpublic entity, this information has not been made publicly available in any other forum. Further, this information is competitively sensitive, and disclosure would cause commercial harm to Party C. (See Or. Rev. Stat. §§ 192.345(2); 192.355(9)(a)). Under ORS 415.501(13)(c), The Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a “material change transaction.” As such, Party C is requesting further confidential treatment of these materials.
HCMO-ATT-1246 to HCMO-ATT-1268 HCMO-ATT-1271 to HCMO-ATT-1287	Party A	<u>Governance Documents</u>	Bylaws and operating agreements relating to Party A and its subsidiaries and affiliates	Party A requests confidential treatment of all nonpublic governance documents related to Party A and its subsidiaries and affiliates. As nonpublic entities, this information has not been made publicly available in any other forum. Further, this information is competitively sensitive, and disclosure would cause commercial harm to Party A. (See Or. Rev. Stat. §§ 192.345(2); 192.355(9)(a)). Under ORS 415.501(13)(c), The Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a “material change transaction.” As such, Party A is requesting further confidential treatment of these materials.

BATES REFERENCE	PARTY INFORMATION	INFORMATION REQUESTED	INFORMATION REDACTED	BASIS FOR REDACTION
HCMO-ATT-1288 to HCMO-ATT-1308 HCMO-ATT-1309 to HCMO-ATT-1311 HCMO-ATT-1338 to HCMO-ATT-1352 HCMO-ATT-1356 to HCMO-ATT-1364	Party B	<u>Governance Documents</u>	Bylaws and operating agreements relating to Party B and its subsidiaries and affiliates	Party B requests confidential treatment of all nonpublic governance documents related to Party B and its subsidiaries and affiliates. As nonpublic entities, this information has not been made publicly available in any other forum. Further, this information is competitively sensitive, and disclosure would cause commercial harm to Party B. (See Or. Rev. Stat. §§ 192.345(2); 192.355(9)(a)). Under ORS 415.501(13)(c), The Oregon Health Authority is prohibited from disclosing any confidential information and documents that are not publicly available that are obtained in relation to a “material change transaction.” As such, Party B is requesting further confidential treatment of these materials.
HCMO-ATT-1365 to HCMO-ATT-1373	Party A, Party B, and Party C	<u>Transaction Documents</u>	Letter of Intent	The parties request confidential treatment of the Parties’ Letter of Intent (the “LOI”). The information redacted in the LOI qualifies as a “trade secret” under ORS 192.345 in that it is non public, competitively sensitive information that relates to the parties’ business strategy and is known only by the executives who have certified this filing, their representatives, and the attorneys who have helped prepare the filing. Further, this information is competitively sensitive and disclosure would enable competitors to identify and exploit vulnerabilities in the companies’ operating models. Pursuant to ORS 415.501(13)(c), the Parties request further confidential treatment of the LOI unless they provide their prior written consent.
HCMO-ATT-1374 to HCMO-ATT-1565	Party A, Party B, and Party C	<u>Transaction Documents</u>	Merger Agreement	The parties request confidential treatment of the Parties’ Merger Agreement (the “Merger Agreement”). The information redacted in the Merger Agreement qualifies as a “trade secret” under ORS 192.345 in that it is non public, competitively sensitive information that relates to the parties’ business strategy and is known only by the executives who have certified this filing, their representatives, and the attorneys who have helped prepare the filing. Further, this information is competitively sensitive and disclosure would enable competitors to identify and exploit vulnerabilities in the companies’ operating models. Pursuant to ORS 415.501(13)(c), the Parties request further confidential treatment of the Merger Agreement unless they provide their prior written consent.

BATES REFERENCE	PARTY INFORMATION	INFORMATION REQUESTED	INFORMATION REDACTED	BASIS FOR REDACTION
HCMO-ATT-1566 to HCMO-ATT-1575	Party A, Party B, and Party C	<u>Transaction Documents</u>	Mutual NDA	The parties request confidential treatment of the Parties' Confidentiality and Non-Disclosure Agreement (the "NDA"). The information redacted in the NDA qualifies as a "trade secret" under ORS 192.345 in that it is non public, competitively sensitive information that relates to the parties' business strategy and is known only by the executives who have certified this filing, their representatives, and the attorneys who have helped prepare the filing. Further, this information is competitively sensitive and disclosure would enable competitors to identify and exploit vulnerabilities in the companies' operating models. Pursuant to ORS 415.501(13)(c), the Parties request further confidential treatment of the NDA unless they provide their prior written consent.